mPRα CRISPR/Cas9 KO Plasmid (h): sc-402143
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- mPRα CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the mPRα genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
mPRα CRISPR/Cas9 KO Plasmid (h) | sc-402143 | 20 µg | $397.00 |
Overview
PAQR7 encodes membrane progesterone receptor alpha (mPRα), a seven-transmembrane progestin receptor in the PAQR family that mediates rapid, non-genomic progesterone signaling at the plasma membrane and intracellular membranes. mPRα influences cellular processes including cyclic nucleotide signaling, kinase cascades, calcium flux, and regulation of apoptosis and cell motility, with context-dependent effects on transcriptional programs through downstream second-messenger pathways. PAQR7 expression has been reported across reproductive and non-reproductive tissues, supporting roles in steroid hormone responsiveness, neuroendocrine regulation, and immune and epithelial signaling. Dysregulated mPRα signaling has been investigated in hormone-responsive biology and in disease-relevant contexts such as reproductive disorders and hormone-associated cancer models, where altered progesterone responsiveness can affect proliferation, invasion, and stress-adaptation pathways.
mPRα CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PAQR7 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PAQR7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PAQR7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish mPRα protein expression.
This CRISPR knockout system enables efficient generation of PAQR7-deficient cell models for investigation of mPRα signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PAQR7 exon(s) critical for mPRα function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PAQR7 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by mPRα CRISPR/Cas9 KO Plasmid (h) and mPRα CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PAQR7 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by mPRα HDR Plasmid (h) and mPRα HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PAQR7 homology arms to support homology-directed repair at defined PAQR7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.